SSA
FATE icon

Schonfeld Strategic Advisors’s Fate Therapeutics FATE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-192,682
Closed -$189K – 2362
2025
Q4 		$189K Sell
192,682
-351,905
-65% -$423K ﹤0.01% 1727
2025
Q3 		$686K Sell
544,587
-386,222
-41% -$416K ﹤0.01% 1546
2025
Q2 		$1.04M Sell
930,809
-6,863,704
-88% -$7.98M 0.01% 1287
2025
Q1 		$6.16M Buy
+7,794,513
New +$9.55M 0.04% 467
2024
Q2 		– Sell
-886,925
Closed -$6.51M – 2280
2024
Q1 		$6.51M Buy
886,925
+389,468
+78% +$2.41M 0.04% 543
2023
Q4 		$1.86M Buy
497,457
+478,257
+2,491% +$1.13M 0.01% 822
2023
Q3 		$40.7K Buy
+19,200
New +$63.6K ﹤0.01% 1544
2023
Q1 		– Sell
-139,000
Closed -$1.4M – 2250
2022
Q4 		$1.4M Buy
139,000
+54,144
+64% +$1.02M 0.01% 984
2022
Q3 		$1.9M Sell
84,856
-15,736
-16% -$455K 0.02% 888
2022
Q2 		$2.49M Buy
+100,592
New +$2.78M 0.02% 684
2021
Q1 		– Sell
-4,117
Closed -$375K – 1893
2020
Q4 		$375K Sell
4,117
-4,996
-55% -$310K 0.01% 1129
2020
Q3 		$364K Buy
+9,113
New +$318K 0.01% 1020
2019
Q4 		– Sell
-96,400
Closed -$1.5M – 1352
2019
Q3 		$1.5M Buy
96,400
+85,035
+748% +$1.63M 0.04% 378
2019
Q2 		$231K Buy
+11,365
New +$205K 0.01% 848
2018
Q4 		– Sell
-116,100
Closed -$1.89M – 1121
2018
Q3 		$1.89M Buy
+116,100
New +$1.37M 0.08% 293

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schonfeld Strategic Advisors's FATE Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Fate Therapeutics (FATE) in Q1 2026, closing a stake of 192,682 shares — an estimated $189K sold.

Schonfeld Strategic Advisors first reported a position in FATE in Q3 2018 and held it in 15 quarters. The position peaked at $6.51M in Q1 2024. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Fate Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 192,682 Fate Therapeutics shares in Q1 2026, an estimated $189K.
  • Schonfeld Strategic Advisors first reported a position in Fate Therapeutics in Q3 2018 and held it in 15 quarters.
  • Schonfeld Strategic Advisors's Fate Therapeutics position peaked at $6.51M in Q1 2024.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.